Business

Announcement on Voluntary Disclosure on Phase II Clinical Trial Data of Oral APL-1202 Combined with Tislelizumab in Neoadjuvant Therapy for Muscle-invasive Bladder Cancer at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium

Announcement on Voluntary Disclosure on Phase II Clinical Trial Data of Oral APL-1202 Combined with Tislelizumab in Neoadjuvant Therapy for Muscle-invasive Bladder Cancer at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium

articleJiangsu Yahong Meditech Co., Ltd. Class AFebruary 14, 20253/news/announcement-on-voluntary-disclosure-on-phase-ii-clinical-trial-data-of-oral-apl-1202-combined-with-tislelizumab-in-neoadjuvant-therapy-for-muscle-invasive-bladder-cancer-at-the-2025-american-society-of-clinical-oncology-asco-genitourinary-cancer-symposium
Announcement on Voluntary Disclosure on Phase II Clinical Trial Data of Oral APL-1202 Combined with Tislelizumab in Neoadjuvant Therapy for Muscle-invasive Bladder Cancer at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium

About this update from Jiangsu Yahong Meditech Co., Ltd. Class A

Announcement on Voluntary Disclosure on Phase II Clinical Trial Data of Oral APL-1202 Combined with Tislelizumab in Neoadjuvant Therapy for Muscle-invasive Bladder Cancer at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancer SymposiumThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Jiangsu Yahong Meditech Co., Ltd. Class A